Depression, Anxiety During Pregnancy Associated with Significant Increase in Adverse Perinatal Outcomes
Diagnosis of a mood or anxiety disorder during pregnancy was associated with a 3.5-fold increase in adverse perinatal outcomes.
Diagnosis of a mood or anxiety disorder during pregnancy was associated with a 3.5-fold increase in adverse perinatal outcomes.
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on the long-term behavioral follow-up of children exposed to mood stabilizers and antidepressants with Ob.Gyn News on August 16,
This meta-analysis is reassuring regarding risk for malformations in children exposed prenatally to oxcarbazepine; however, we still need more data to fully assess reproductive safety.
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Data from a Nordic register-based study observed a significant increase in risk for autism spectrum disorder and intellectual disability in children with prenatal exposure to topiramate.
Largest studies to date demonstrate statistically significant risk of preterm birth among women with active PTSD.
The use of valproic acid during pregnancy is associated with a significant increase in risk of major malformations and neurodevelopmental disorders. Given these risks, should it be a treatment option for women of childbearing age?
Every week we review the most recent publications in women’s mental health.
Depression and anxiety are prevalent among women who have experienced a stillbirth, especially those reporting inadequate paternal support
A recent review and meta-analysis found that upwards of 20% of women with no history of psychiatric illness experience their first bipolar-spectrum mood episode during the perinatal period.